125 related articles for article (PubMed ID: 17011068)
1. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
[TBL] [Abstract][Full Text] [Related]
2. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E; Thöm I; Krüll A; Engel-Riedel W; Müller T; Meissner C; Dürk H; Fischer J; Gütz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Görn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C
Lung Cancer; 2007 Aug; 57(2):181-6. PubMed ID: 17442447
[TBL] [Abstract][Full Text] [Related]
5. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Hermes A; Bergman B; Bremnes R; Ek L; Fluge S; Sederholm C; Sundstrøm S; Thaning L; Vilsvik J; Aasebø U; Sörenson S
J Clin Oncol; 2008 Sep; 26(26):4261-7. PubMed ID: 18779613
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
Murata Y; Hirose T; Yamaoka T; Shirai T; Okuda K; Sugiyama T; Kusumoto S; Nakashima M; Ohmori T; Adachi M
Eur J Cancer; 2011 Jun; 47(9):1336-42. PubMed ID: 21458256
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
Jeong HC; Lee SY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
Lung Cancer; 2006 Sep; 53(3):361-6. PubMed ID: 16846662
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Horn L; Zhao Z; Sandler A; Johnson D; Shyr Y; Wolff S; Devore RF; Laskin J
Clin Lung Cancer; 2011 May; 12(3):161-5. PubMed ID: 21663858
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
Kinoshita A; Fukuda M; Soda H; Nagashima S; Fukuda M; Takatani H; Kuba M; Nakamura Y; Tsurutani J; Kohno S; Oka M;
Br J Cancer; 2006 May; 94(9):1267-71. PubMed ID: 16622467
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Spigel DR; Hainsworth JD; Simons L; Meng C; Burris HA; Yardley DA; Grapski R; Schreeder M; Mallidi PV; Greco FA;
J Thorac Oncol; 2007 Sep; 2(9):854-61. PubMed ID: 17805064
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]